Characteristics of the UM171, CB, and MUD PBSC controls
| Characteristic . | UM171 CB . | CB controls . | MUD PBSC controls . | ||
|---|---|---|---|---|---|
| . | N (%) . | P UM171 CB vs CB controls . | N (%) . | P UM171 CB vs PBSC controls . | |
| Number of patients | 22 | 67 | 70 | ||
| Patient age, median (range), y | 45 (19-63) | 45 (19-63) | .68∗ | 39 (18-63) | .38∗ |
| First alloHCT | .30† | .35† | |||
| No | 5 (23) | 9 (13) | 10 (14) | ||
| Yes | 17 (77) | 58 (87) | 60 (86) | ||
| Disease | .81† | .89† | |||
| AML | 8 (36) | 30 (45) | 31 (44) | ||
| ALL | 8 (36) | 23 (34) | 23 (33) | ||
| CML | 1 (5) | 4 (6) | 4 (6) | ||
| NHL/HL | 5 (23) | 10 (15) | 12 (17) | ||
| Refined Disease Risk Index | .31† | .76† | |||
| Low | 4 (18) | 4 (6) | 8 (11) | ||
| Intermediate | 8 (36) | 35 (52) | 32 (46) | ||
| High | 4 (18) | 16 (24) | 16 (23) | ||
| Very high | 1 (5) | 3 (4) | 4 (6) | ||
| N/A, second alloHCT | 5 (23) | 9 (13) | 10 (14) | ||
| Disease status for second alloHCT (AML/ALL) | .43† | .59† | |||
| Intermediate | 3 (14) | 7 (10) | 7 (10) | ||
| Advanced | 2 (9) | 2 (3) | 3 (4) | ||
| N/A, first alloHCT | 17 (77) | 58 (87) | 30 (86) | ||
| Modified ELN for AML | .77† | .84† | |||
| Favorable | 0 (0) | 1 (1) | 1 (1) | ||
| Intermediate | 6 (27) | 18 (27) | 20 (29) | ||
| Adverse | 2 (9) | 11 (16) | 10 (14) | ||
| N/A | 14 (64) | 37 (55) | 39 (56) | ||
| HCT-CI | .89† | .79† | |||
| 0 | 8 (36) | 23 (34) | 21 (30) | ||
| 1-2 | 6 (27) | 22 (33) | 18 (26) | ||
| ≥ 3 | 8 (36) | 22 (33) | 31 (44) | ||
| KPS | .42† | .87† | |||
| < 90 | 13 (59) | 33 (49) | 40 (57) | ||
| 90-100 | 9 (41) | 34 (51) | 30 (43) | ||
| Characteristic . | UM171 CB . | CB controls . | MUD PBSC controls . | ||
|---|---|---|---|---|---|
| . | N (%) . | P UM171 CB vs CB controls . | N (%) . | P UM171 CB vs PBSC controls . | |
| Number of patients | 22 | 67 | 70 | ||
| Patient age, median (range), y | 45 (19-63) | 45 (19-63) | .68∗ | 39 (18-63) | .38∗ |
| First alloHCT | .30† | .35† | |||
| No | 5 (23) | 9 (13) | 10 (14) | ||
| Yes | 17 (77) | 58 (87) | 60 (86) | ||
| Disease | .81† | .89† | |||
| AML | 8 (36) | 30 (45) | 31 (44) | ||
| ALL | 8 (36) | 23 (34) | 23 (33) | ||
| CML | 1 (5) | 4 (6) | 4 (6) | ||
| NHL/HL | 5 (23) | 10 (15) | 12 (17) | ||
| Refined Disease Risk Index | .31† | .76† | |||
| Low | 4 (18) | 4 (6) | 8 (11) | ||
| Intermediate | 8 (36) | 35 (52) | 32 (46) | ||
| High | 4 (18) | 16 (24) | 16 (23) | ||
| Very high | 1 (5) | 3 (4) | 4 (6) | ||
| N/A, second alloHCT | 5 (23) | 9 (13) | 10 (14) | ||
| Disease status for second alloHCT (AML/ALL) | .43† | .59† | |||
| Intermediate | 3 (14) | 7 (10) | 7 (10) | ||
| Advanced | 2 (9) | 2 (3) | 3 (4) | ||
| N/A, first alloHCT | 17 (77) | 58 (87) | 30 (86) | ||
| Modified ELN for AML | .77† | .84† | |||
| Favorable | 0 (0) | 1 (1) | 1 (1) | ||
| Intermediate | 6 (27) | 18 (27) | 20 (29) | ||
| Adverse | 2 (9) | 11 (16) | 10 (14) | ||
| N/A | 14 (64) | 37 (55) | 39 (56) | ||
| HCT-CI | .89† | .79† | |||
| 0 | 8 (36) | 23 (34) | 21 (30) | ||
| 1-2 | 6 (27) | 22 (33) | 18 (26) | ||
| ≥ 3 | 8 (36) | 22 (33) | 31 (44) | ||
| KPS | .42† | .87† | |||
| < 90 | 13 (59) | 33 (49) | 40 (57) | ||
| 90-100 | 9 (41) | 34 (51) | 30 (43) | ||